Aflibercept for resistant eye swelling and new blood vessels
Part of Eyes & vision, Heart & circulation clinical trials.
This trial tests a higher dose of aflibercept (8 mg) for people whose diabetic macular edema, retinal vein occlusion, or myopic choroidal neovascularization has not improved with standard treatment. The goal is to see if this stronger dose can reduce fluid and improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have diabetic macular edema, retinal vein occlusion, or myopic choroidal neovascularization that has not responded to standard treatments.
- You have not had eye surgery in the past.
- You do not have other eye conditions like age-related macular degeneration or choroiditis.
- You have not had laser treatment or steroid injections for your eye condition.
- You do not have glaucoma or eye pressure of 20 mmHg or higher.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This study tests whether one eye injection (aflibercept) works better than another (bevacizumab) for people with diabetic macular edema. Both are already used for this condition, and the goal is to see which provides better vision improvement.
This trial tests if combining a steroid implant (dexamethasone) with an anti-VEGF injection (aflibercept) works better than aflibercept alone for people with diabetic macular edema caused by inflammation. It aims to find the best first treatment for improving vision and reducing swelling.
This trial compares a new treatment (EYP-1901, given as an injection) to a standard injection (aflibercept) for people with diabetic macular edema. It aims to see which works better at reducing swelling and improving vision.
This study compares a new medication, tabirafusp tedromer, to an existing treatment, aflibercept, for people with diabetic macular edema (swelling in the back of the eye from diabetes). It may help if your DME hasn't improved or you're looking for a new option.
This phase 3 trial tests a new long-acting injection (EYP-1901) against a standard one (aflibercept) for people with diabetic macular edema. Both treatments are given as eye injections, and the goal is to see if the new drug works as well and may require fewer injections.
Hear when a new Diabetic Macular Edema (DME) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.